Tetra Bio-Pharma has announced results from the artificial intelligence (AI) study of ARDS-003, along with Favipiravir, against acute respiratory distress syndrome (ARDS), Sepsis, and Covid-19 through the PREPAiRE platform.
NASSAU, Bahamas--(BUSINESS WIRE)--ABO, a family office founded by Pierre Vannineuse and a pioneer in alternative finance worldwide, is proud to support Tetra Bio-Pharma’s growth initiatives with the recent financing agreement of up to CAD 10 million in convertible debentures.
Tetra Bio-Pharma and Cellvera have entered an agreement to jointly develop ARDS-003 as an oral combination therapeutic candidate with 400mg Qifenda (Favipiravir) for Covid-19.
Tetra Bio-Pharma Inc. has signed an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product, with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug.
Tetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003